# Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic Cancer

> **NCT04191421** · PHASE1,PHASE2 · COMPLETED · sponsor: **Emory University** · enrollment: 35 (actual)

## Conditions studied

- Metastatic Pancreatic Adenocarcinoma
- Stage IV Pancreatic Cancer AJCC v8

## Interventions

- **BIOLOGICAL:** Siltuximab
- **BIOLOGICAL:** Spartalizumab

## Key facts

- **NCT ID:** NCT04191421
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-17
- **Primary completion:** 2023-04-05
- **Final completion:** 2023-04-05
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2025-08-22

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04191421

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04191421, "Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT04191421. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*